FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
|Articles|August 1, 2001
Supplements and Featured Publications
- The Need for Cholesterol Control: Clinical and Managed Care Concerns
- Volume 7
- Issue 9 Suppl
Lipid Management: Tools for Getting to the Goal
Author(s)James M. McKenney, PharmD
Advertisement
Articles in this issue
about 25 years ago
Participating Facultyabout 25 years ago
Introductionabout 25 years ago
Cholesterol: Precursor to Many Lipid Disordersabout 25 years ago
Identifying All Suspects: Case Studiesabout 25 years ago
Continuing Pharmacy/Nursing Education Quizabout 25 years ago
Literature ReviewAdvertisement
Related to this article
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.
Advertisement
Advertisement
Trending on AJMC
1
New CHEST Guidelines Offer a Road Map for Bronchiectasis
2
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
3
Pathological Response Does Not Reliably Predict Survival in Sarcoma
4
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
5